From the Journals

Neuropsychiatric risks of COVID-19: New data


 

Caveats, cautionary notes

Kevin McConway, PhD, emeritus professor of applied statistics at the Open University in Milton Keynes, England, described the study as “impressive.” However, he pointed out that the study’s observational design is a limitation.

“One can never be absolutely certain about the interpretation of findings of an observational study. What the research can’t tell us is what caused the increased psychiatric risks for people hospitalized with COVID-19 or some other serious respiratory disease,” Dr. McConway said.

“It can’t tell us what might happen in the future, when, we all hope, many fewer are being hospitalized with COVID-19 than was the case in those first two waves, and the current backlog of provision of some health services has decreased,” he added.

“So we can’t just say that, in general, serious COVID-19 has much the same neuropsychiatric consequences as other very serious respiratory illness. Maybe it does, maybe it doesn’t,” Dr. McConway cautioned.

Max Taquet, PhD, with the University of Oxford, noted that the study is limited to hospitalized adult patients, leaving open the question of risk in nonhospitalized individuals – which is the overwhelming majority of patients with COVID-19 – or in children.

Whether the neuropsychiatric risks have remained the same since the emergence of the Omicron variant also remains “an open question since all patients in this study were diagnosed before July 2021,” Dr. Taquet said in statement.

The study was funded by the Wellcome Trust, the John Fell Oxford University Press Research Fund, the Oxford Wellcome Institutional Strategic Support Fund and Cancer Research UK, through the Cancer Research UK Oxford Centre. Dr. Watkinson disclosed grants from the National Institute for Health Research and Sensyne Health outside the submitted work; and serving as chief medical officer for Sensyne Health prior to this work, as well as holding shares in the company. Dr. McConway is a trustee of the UK Science Media Centre and a member of its advisory committee. His comments were provided in his capacity as an independent professional statistician. Dr. Taquet has worked on similar studies trying to identify, quantify, and specify the neurological and psychiatric consequences of COVID-19.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Michigan COVID cases possibly the first from animals in U.S.
MDedge Neurology
30% of COVID patients in study developed long COVID
MDedge Neurology
CDC panel lists reasons to get second COVID booster
MDedge Neurology
Myocarditis higher with Moderna COVID vax in young men
MDedge Neurology
One in four feel fully recovered following COVID-19 hospitalization
MDedge Neurology
Almost 60% of U.S. population has been infected by COVID-19: CDC
MDedge Neurology
Two MS meds tied to higher COVID rates
MDedge Neurology
New data confirm risk of Guillain-Barré with J&J COVID shot
MDedge Neurology
When it’s not long, but medium COVID?
MDedge Neurology
FDA limits use of J&J COVID vaccine over blood clot risk
MDedge Neurology